PRELIMINARY RESULTS FROM A SAFETY AND TOLERABILITY STUDY OF THE PHARMACEUTICAL COMPOSITION BASED ON DIINDOLYLMETHANE IN PATIENTS WITH ENDOMETRIAL HYPERPLASIA WITHOUT ATYPIA

Read the publication (PDF) — 482.1 KB

Other publications

3,3′-Diindolylmethane Improves the Viral Pneumonia Outcomes After Influenza and SARS-CoV-2 Infection in Animal Models

Preclinical antitumor activity of the diindolylmethane formulation in xenograft mouse model of prostate cancer

Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)

Comparative preclinical pharmacokinetics study of 3,3?-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon?

Contact us

Select a service*

Pharmacovigilance

MiraxBioPharma is committed to ensuring the quality and safety of its products and pays special attention to collecting and analyzing information about adverse reactions and complaints associated with the use of our products.

If you become aware of any adverse reactions to the medicinal product Cezarox® Epi or of a lack of therapeutic effect, please report it via email at: adversareaction@drugsafety.ru or by phone: +7 (800) 777-86-04.

If you become aware of any adverse reactions to other MiraxBioPharma medicinal products or of a lack of therapeutic effect, please report it via email at: GVP@mbpharma.ru, by phone: +7 (495) 721-20-58 or by filling out the electronic form below

Adverse reaction reporting form
Specify gender*
Suspected medicinal product information
Reporter information

Preferred method of contact*